Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Burke

Clinical Cardiac Electrophysiology Newtown, PA Medical Doctor

NPI 1164488987 CMS profile 7257

104 Pheasant Run, Newtown, PA 18940

Open in the dashboard

General payments

$16,252

328 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$26,827 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Scott Burke of Newtown, PA is reported in the CMS Open Payments database as having received $16,252 across 328 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $26,827 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 46th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,302 31
2024 General $2,906 50
2023 General $2,951 82
2022 General $1,319 44
2021 General $482 34
2020 General $401 35
2019 General $6,892 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Burke
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Scott Burke were reported at $1,302. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Scott Burke Clinical Cardiac Electrophysiology median Middle half National median
2019 $6,892 $2,361 $585–$8,260 $163
2020 $401 $993 $247–$4,351 $114
2021 $482 $1,185 $326–$4,739 $132
2022 $1,319 $2,073 $554–$6,789 $149
2023 $2,951 $2,568 $759–$8,159 $160
2024 $2,906 $2,557 $703–$7,403 $164
2025 $1,302 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $9,356 90 payments
  2. Abbott Laboratories $2,223 40 payments
  3. Biosense Webster, Inc. $1,982 102 payments
  4. Biotronik Inc. $1,214 27 payments
  5. Medtronic, Inc. $496 8 payments
  6. Janssen Pharmaceuticals, Inc $157 11 payments
  7. Pfizer Inc. $135 10 payments
  8. Amgen Inc. $100 6 payments
  9. Novartis Pharmaceuticals Corporation $71 5 payments
  10. Medtronic Vascular, Inc. $71 4 payments
  11. Other $446 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,153 312 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,000 2 payments
  3. Travel and Lodging $2,099 14 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN $6,355 9 payments
  2. Carto 3 $1,528 40 payments
  3. AVEIR $1,290 24 payments
  4. BIOMONITOR $686 18 payments
  5. WATCHMAN FLX $639 22 payments
  6. AMVIA EDGE $473 8 payments
  7. WATCHMAN Access System $343 24 payments
  8. OCTARAY MAPPING CATHETER $324 23 payments
  9. FARAPULSE $295 7 payments
  10. Confidense $176 23 payments
  11. Other $3,020 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,375

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$591,702

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

45.7%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 248 $321,548
Xarelto Rivaroxaban Brand 87 $121,901
Multaq Dronedarone Hcl Brand 72 $97,737
Dofetilide Generic 126 $22,364
Propafenone Hcl Er Propafenone Hcl Brand 37 $8,285
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 123 $5,709
Flecainide Acetate Generic 69 $3,848
Metoprolol Succinate Generic 191 $2,792
Amiodarone Hcl Generic 61 $1,905
Nadolol Generic 17 $882

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$226,726

Medicare's payments for the services billed

Medicare patients

791

Average age 77

Services billed

4,004

297 women, 494 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 61%
Heart failure 51%
Arthritis 44%
Diabetes 37%
Chronic kidney disease 32%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $36
$36 87 —
Repatha
  • Amgen Inc. $19
$19 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $16
$16 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

328 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record